Investment
Features
FeesSafety
Academy
More
Pluang+

Vertex Pharmaceuticals offers a strong long-term buy with its cystic fibrosis monopoly and robust cash flow.

Market News
02 Jun 2026
24/7 Wall Street
View Source
Bullish
pluang ai news

Vertex Pharmaceuticals holds a global monopoly in cystic fibrosis therapies, generating substantial free cash flow with products like TRIKAFTA/KAFTRIO and ALYFTREK. Its business is recession-resistant, supported by expanding patient eligibility and strong financials including $3.19 billion free cash flow in 2025. Despite some setbacks in other drug programs, Vertex’s cash-rich position and pipeline developments position it well for long-term value growth, making it ideal for patient investors rather than short-term traders.

More News (VRTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App